Market Research Logo

Metabolic Disorder Drugs Market Global Briefing 2017Including: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).Covering: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck

Metabolic Disorder Drugs Market Global Briefing 2017Including: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).Covering: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG

The global metabolic disorder drugs market is expected to reach around $110 billion in 2020. The market is expected to be driven by rapid growth in diabetic patients which, according to the World Health Organization, is expected to be the world’s seventh leading cause of death in 2030.

Metabolic Disorder Drugs Market Global Briefing provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorder drugs sector.

Reasons to Purchase

  • Get up to date information available on the metabolic disorder drugs market globally.
  • Identify growth segments and opportunities.
  • Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
  • Develop strategies based on likely future developments.
  • Gain a global perspective on the development of the market.
Description

Metabolic Disorder Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the metabolic disorder drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the metabolic disorder drugs market and suggests approaches.

Scope

Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
Companies Mentioned: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.


Metabolic Disorder Drugs Market Characteristics
Metabolic Disorder Drugs Market Historic Growth
Metabolic Disorder Drugs Market Forecast Growth
Metabolic Disorder Drugs Market Segmentation
Global Metabolic Disorder Drugs Market, Split By Segments, 2016, $ Billion
Anti-diabetics Drugs
Anti-thyroid drugs
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)
Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segments, 2012-2020
Metabolic Disorder Drugs Market Geography Regional and Country Comparison
Global Metabolic Disorder Drugs Market, Split By Regions, 2016
Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020
Global Metabolic Disorder Drugs Market, Split By Country, 2016
Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020
Metabolic Disorder Drugs Market Competitive Landscape
Sanofi S.A.
Novo Nordisk A/S
AstraZeneca Plc.
Johnson & Johnson
Merck & Co.
Abbott Laboratories Inc.
Boehringer Ingelheim GmbH
Pfizer Inc.
AbbVie Inc.
Takeda Pharmaceuticals
Sanofi
Novo Nordisk
AstraZeneca PLC
Metabolic Disorders Drugs Market Key Mergers And Acquisitions
Alexion Acquired Synageva
AstraZeneca Acquired ZS Pharma
Horizon Pharma Plc. Acquired Hyperion Therapeutics, Inc.
Horizon Pharma Plc. Acquired Raptor Pharmaceutical Corp.
Madrigal Pharmaceuticals Merged With Synta Pharmaceuticals Corp.
Metabolic Disorders Drugs Market Trends And Strategies
Development Of New Anti-Diabetic Drugs For Type 2 Diabetes
Enzyme Replacement Therapies For The Treatment Of Of Rare Metabolic Disorders
Increase In Mergers And Acquisitions
Appendix
NAICS Definitions Of Industry Covered In This Report
Definition Of Market Covered In This Report
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism.
Abbreviations
Currencies
Research Methodology
Research Inquiries
The Business Research Company
List of Figures
Figure 1: Global Metabolic Disorder Drugs Market, Historic Market Size, 2012-2016, $ Billion
Figure 2: Global Metabolic Disorder Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion
Figure 3: Global Metabolic Disorder Drugs Market, Split By Segments, 2016, $ Billion
Figure 4: Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020
Figure 5: Global Metabolic Disorder Drugs Market, Split By Region, 2016, $ Billion
Figure 6: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020
Figure 7: Global Metabolic Disorder Drugs Market, Split By Country, 2016, $ Billion
Figure 8: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020
Figure 9: Global Metabolic Disorder Drugs Market, Key Competitor Market Shares, 2016, Percentage (%)
List of Tables
Table 1: Global Metabolic Disorder Drugs Market, Historic Market Size, 2012-2016, $ Billion
Table 2: Global Metabolic Disorder Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion
Table 3: Global Metabolic Disorder Drugs Market, Split By Segments, 2016, $ Billion
Table 4: Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020
Table 5: Global Metabolic Disorder Drugs Market, Split By Region, 2016, $ Billion
Table 6: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020
Table 7: Global Metabolic Disorder Drugs Market, Split By Country, 2016, $ Billion
Table 8: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020
Table 9: Global Metabolic Disorder Drugs Market, Key Competitor Market Shares, 2016, Percentage (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report